Phase II study of a combined Paclitaxel, Gemcitabine, and Cisplatin chemotherapy regimen for advanced urothelial carcinoma

Phase II study of a combined Paclitaxel, Gemcitabine, and Cisplatin chemotherapy regimen for advanced urothelial carcinoma - Phase II study of a TGP chemotherapy regimen for advanced urothelial carcinoma

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001979

Enrollment

Registered

2009-05-18

Start date

2009-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced urothelial carcinoma

Interventions

Paclitaxel 80mg/m2

day 1, 8 Gemcitabine 1000mg/m2

day 1, 8 Cisplatin 50mg/m2

day 2

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: PS 0-2 advanced urothelial carcinoma Ccr: more than 50ml/min

Exclusion criteria

Exclusion criteria: no other active malignancy Acute myocardial infarction within 3 months of this study

Design outcomes

Primary

Measure	Time frame
response rate	—

Secondary

Measure	Time frame
1) safety 2)progression-free survival	—

Countries

Japan

Contacts

Public ContactYamamoto Shinya

Cancer Institute Hospital, Japanese Foundation for Cancer Research Urology

shinya.yamamoto@jfcr.or.jp03-3520-0111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026